Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The D(3) dopamine receptor (DRD3) is a G protein-coupled receptor that primarily inhibits adenylyl cyclase, reducing cAMP levels. It is predominantly expressed in the ventral striatum, thalamus, hippocampus, and cortex. DRD3 modulates dopaminergic neurotransmission and regulates neuronal excitability. It is implicated in schizophrenia, Parkinson's disease, drug addiction, and depression and is considered a promising therapeutic target.
Agonism or antagonism/partial agonism of the dopamine D3 receptor, modulating downstream signaling pathways involving cAMP and neuronal excitability.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dopamine Receptor D(3) (DRD3).